Essex Investment Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Essex Investment Management’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-29	Closed	-$4K	–	516
2020 Q4	$4K	Sell	29 -9,805	-100%	-$1.29M	﹤0.01%	462
2020 Q3	$958K	Buy	+9,834	New	+$1.23M	0.14%	223
2020 Q2	–	Sell	-10,000	Closed	-$1.44M	–	456
2020 Q1	$1.44M	Hold	10,000	–	–	0.29%	108
2019 Q4	$2.04M	Buy	+10,000	New	+$1.82M	0.25%	134
2018 Q2	–	Sell	-20,557	Closed	-$422K	–	434
2018 Q1	$422K	Buy	+20,557	New	+$529K	0.06%	278

Other funds holding RETA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Essex Investment Management's RETA Position: Q1 2021 in Review

Essex Investment Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q1 2021, closing a stake of 29 shares — an estimated $4K sold.

Essex Investment Management first reported a position in RETA in Q1 2018 and held it in 5 quarters. The position peaked at $2.04M in Q4 2019. 201 funds tracked by Wall St. Rank hold RETA as of Q1 2021.

Essex Investment Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q1 2021 after selling out during the quarter.
Essex Investment Management sold 29 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q1 2021, an estimated $4K.
Essex Investment Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2018 and held it in 5 quarters.
Essex Investment Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $2.04M in Q4 2019.
201 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q1 2021.

Based on Essex Investment Management's 13F filing for Q1 2021, filed 12 May 2021.